

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2018/2019 influenza season**

as of August 20, 2019

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	6 <sup>a</sup> (1.8%)	17 <sup>b</sup> (0.8%)	17 <sup>b</sup> (0.8%)	0	0	188 (100%)	34 <sup>c</sup> (9.6%)	0	0	0	0	155 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	330	2,099	2,099	316	316	188	356	322	322	322	322	155	40	95	95	95	95
<b>Number of viruses reported</b>	2,979						4,601						567				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>a</sup> Patients without treatment 0

<sup>b</sup> Patients without treatment 4

<sup>c</sup> Patients without treatment 4